[1] Chen CH,Chiu YC,Lu SN,et al.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues[J].World J Gastroenterol,2014,20(24):7686-7695.
[2] Trepo C,Chan HL,Lok A.Hepatitis B virus infection[J].Lancet,2014,384(9959):2053-2063.
[3] 乔伟振,李另另,谢平,等.非霍奇金淋巴瘤患者HBV感染状况及HBV DNA载量分析[J].重庆医学,2013,42(4):420-422.
[4] Martinot-Peignoux M,Lapalus M,Asselah T,et al.HBsAg quantification:useful for monitoring natural history and treatment outcome[J].Liver Int,2014,34(Suppl 1):97-107.
[5] Ning Q,Han M,Sun Y,et al.Switching from entecavir to PegIFN α-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial(OSST trial)[J].J Hepatol,2014,61(4):777-784.
[6] 裴彦祯, 韩涛,马晓艳,等.HBsAg及HBV DNA定量水平在慢性乙型肝炎、肝硬化和肝癌患者中的变化[J].中华肝脏病杂志,2011,19(10):743-746.
[7] Thompson AJ,Nguyen T,Iser D,et al.Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers[J].Hepatology,2010,51(6):1933-1944.
[8] 成军,孙长贵,陈瑜,等.低浓度HBsAg人群HBV DNA与HBV M定量结果的关系及评价[J].细胞与分子免疫学杂志,2009,25(7):631-636.
[9] Li M,Xi H,Wang Q,et al.Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment[J].Chin Med J(Engl),2014,127(11):2101-2104.
[10] Alghamdi A,Aref N,El-Hazmi M,et al.Correlation between hepatitis B surface antigen titers and HBV DNA levels[J].Saudi J Gastroenterol,2013,19(6):252-257.
[11] Wiegand J,Wedemeyer H,Finger A,et al.A decline in hepatitis B virus surface antigen(hbsag) predicts clearance,but does not correlate with quantitative hbeag or HBV DNA levels[J].Antivir Ther,2008,13(4):547-554.
[12] Ozdil B,Cosar AM,Akkiz H,et al.Negative correlation between viral load and HBsAg levels in chronic HBV-infected patients[J].Arch Virol,2009,154(9):1451-1455.
[13] 郭龙华,陈茶,万泽民,等.乙型肝炎病毒基因组1896位点变异株与野生株的定性检测[J].重庆医学,2013,42(3):308-309.